Ardent Health Partners, LLC (NYSE:ARDT) Receives $20.75 Consensus Price Target from Analysts

Ardent Health Partners, LLC (NYSE:ARDT - Get Free Report) has been assigned a consensus rating of "Buy" from the thirteen brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $20.75.

Several brokerages recently issued reports on ARDT. Mizuho reduced their price target on shares of Ardent Health Partners from $19.00 to $18.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Stephens restated an "overweight" rating and issued a $22.00 price target on shares of Ardent Health Partners in a research report on Tuesday, April 1st. Guggenheim raised their target price on shares of Ardent Health Partners from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $21.00 price target on shares of Ardent Health Partners in a report on Thursday. Finally, Morgan Stanley decreased their price objective on Ardent Health Partners from $23.50 to $22.00 and set an "overweight" rating for the company in a report on Tuesday, January 21st.

Institutional Trading of Ardent Health Partners

Several hedge funds have recently added to or reduced their stakes in the stock. Ventas Inc. bought a new stake in shares of Ardent Health Partners during the fourth quarter valued at approximately $159,570,000. Vanguard Group Inc. grew its holdings in Ardent Health Partners by 368.9% in the 1st quarter. Vanguard Group Inc. now owns 1,330,635 shares of the company's stock valued at $18,296,000 after buying an additional 1,046,845 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Ardent Health Partners by 1,684.9% during the first quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company's stock worth $10,558,000 after acquiring an additional 724,841 shares during the period. Nuveen LLC acquired a new position in Ardent Health Partners in the first quarter valued at $6,010,000. Finally, Segall Bryant & Hamill LLC acquired a new stake in shares of Ardent Health Partners during the 4th quarter valued at approximately $4,478,000.

Ardent Health Partners Price Performance

Shares of Ardent Health Partners stock traded down $0.15 during trading on Wednesday, reaching $15.27. 28,002 shares of the company's stock were exchanged, compared to its average volume of 396,057. Ardent Health Partners has a 1-year low of $11.31 and a 1-year high of $20.72. The firm's 50-day moving average price is $13.13 and its 200 day moving average price is $14.81. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.78 and a current ratio of 1.91. The company has a market cap of $2.18 billion and a P/E ratio of 9.37.

Ardent Health Partners (NYSE:ARDT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.21 by $0.08. The firm had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.50 billion. As a group, research analysts anticipate that Ardent Health Partners will post 1.23 earnings per share for the current year.

Ardent Health Partners Company Profile

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.